To better understand the role of low-dose ATG in T1D intervention efforts and to identify markers predictive of response, mechanistic exploratory analyses were performed on samples from the Type 1 Diabetes TrialNet (TN19) ATG/G-CSF New Onset clinical trial (ClinicalTrials.gov NCT02215200). This evidence concerns the gene CSF3 and type 1 diabetes mellitus.